These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Cohen MH; Dagher R; Griebel DJ; Ibrahim A; Martin A; Scher NS; Sokol GH; Williams GA; Pazdur R Oncologist; 2002; 7(5):393-400. PubMed ID: 12401901 [TBL] [Abstract][Full Text] [Related]
5. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Vogel CL; Yanagihara RH; Wood AJ; Schnell FM; Henderson C; Kaplan BH; Purdy MH; Orlowski R; Decker JL; Lacerna L; Hohneker JA Oncologist; 2004; 9(6):687-95. PubMed ID: 15561812 [TBL] [Abstract][Full Text] [Related]
6. Recommendations for zoledronic acid treatment of patients with bone metastases. Berenson JR Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252 [TBL] [Abstract][Full Text] [Related]
8. FDA approves new drug for treatment of erectile dysfunction in men. FDA Consum; 2003; 37(5):7. PubMed ID: 14666896 [No Abstract] [Full Text] [Related]
9. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536 [TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates and metastatic breast carcinoma. Lipton A Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585 [TBL] [Abstract][Full Text] [Related]
11. [The role of bisphosphonates in the treatment of bone metastases from urogenital cancer ]. Colombel M Prog Urol; 2003 Apr; 13(2 Suppl 1):18-23. PubMed ID: 12815805 [No Abstract] [Full Text] [Related]
12. Bisphosphonates for cancer patients: why, how, and when? Body JJ; Mancini I Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223 [TBL] [Abstract][Full Text] [Related]
13. Zoledronate in the treatment of osteolytic bone metastases. Lipton A Br J Clin Pract Suppl; 1996 Sep; 87():21; discussion 22. PubMed ID: 8995015 [No Abstract] [Full Text] [Related]
14. FDA approves first drug in new treatment category. AIDS Policy Law; 2003 Mar; 18(6):3. PubMed ID: 12712927 [No Abstract] [Full Text] [Related]
15. Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. Breen TL; Shane E J Clin Oncol; 2004 Apr; 22(8):1531-2. PubMed ID: 15084635 [No Abstract] [Full Text] [Related]
16. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Marx RE; Sawatari Y; Fortin M; Broumand V J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172 [TBL] [Abstract][Full Text] [Related]
17. FDA notifications. FDA approves new Kaletra formulation. AIDS Alert; 2005 Dec; 20(12):142-3. PubMed ID: 16400722 [No Abstract] [Full Text] [Related]
18. FDA notifications. FDA approves generic foscarnet sodium injection. AIDS Alert; 2005 Jul; 20(7):82. PubMed ID: 16110563 [No Abstract] [Full Text] [Related]
19. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243 [TBL] [Abstract][Full Text] [Related]
20. FDA notifications. FDA approves generic stavudine. AIDS Alert; 2009 Mar; 24(3):34. PubMed ID: 19441156 [No Abstract] [Full Text] [Related] [Next] [New Search]